Under a model of PD-1 overexpression in exhausted T cells in cancer conditions, it has been suggested that the promoter region of PD-1 is demethylated,14 providing a possible novel approach for ICB therapy, by which DNA methylation of the promoter is upregulated. The gene discussed is PDCD1; the disease is cancer.